BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36806944)

  • 1. Current advances in house dust mite allergen immunotherapy (AIT): Routes of administration, biomarkers and molecular allergen profiling.
    Batard T; Canonica WG; Pfaar O; Shamji MH; O'Hehir RE; van Zelm MC; Mascarell L
    Mol Immunol; 2023 Mar; 155():124-134. PubMed ID: 36806944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis.
    Zhao L; Zhang Y; Zhang S; Zhang L; Lan F
    Expert Rev Clin Immunol; 2021 Sep; 17(9):969-975. PubMed ID: 34388949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy comparison and safety analysis of subcutaneous specific immunotherapy with standardized house dust mite allergen in patients with single and multiple allergic rhinitis].
    Huang HH; Xu C; Liu L; Chai RN
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jun; 56(6):774-783. PubMed ID: 35785859
    [No Abstract]   [Full Text] [Related]  

  • 5. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
    Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of subcutaneous house dust mite immunotherapy in patients with moderate to severe allergic rhinitis.
    Valero A; Ibáñez-Echevarría E; Vidal C; Raducan I; Castelló Carrascosa JV; Sánchez-López J
    Immunotherapy; 2022 Jun; 14(9):683-694. PubMed ID: 35465692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma.
    Eifan AO; Calderon MA; Durham SR
    Expert Opin Biol Ther; 2013 Nov; 13(11):1543-56. PubMed ID: 24099116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.
    Agache I; Lau S; Akdis CA; Smolinska S; Bonini M; Cavkaytar O; Flood B; Gajdanowicz P; Izuhara K; Kalayci O; Mosges R; Palomares O; Papadopoulos NG; Sokolowska M; Angier E; Fernandez-Rivas M; Pajno G; Pfaar O; Roberts GC; Ryan D; Sturm GJ; van Ree R; Varga EM; van Wijk RG; Yepes-Nuñez JJ; Jutel M
    Allergy; 2019 May; 74(5):855-873. PubMed ID: 31095767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of IgE sensitization in house dust mite-allergic patients: implications for allergen immunotherapy.
    Batard T; Baron-Bodo V; Martelet A; Le Mignon M; Lemoine P; Jain K; Mariano S; Horiot S; Chabre H; Harwanegg C; Marquette CA; Corgier BP; Soh WT; Satitsuksanoa P; Jacquet A; Chew FT; Nony E; Moingeon P
    Allergy; 2016 Feb; 71(2):220-9. PubMed ID: 26485347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of rush-subcutaneous and sublingual immunotherapy with house dust mite extract for pediatric allergic rhinitis: A prospective cohort study.
    Hamada M; Saeki K; Tanaka I
    Allergol Int; 2023 Oct; 72(4):573-579. PubMed ID: 36918306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods for Experimental Allergen Immunotherapy: Subcutaneous and Sublingual Desensitization in Mouse Models of Allergic Asthma.
    Hesse L; Petersen AH; Nawijn MC
    Methods Mol Biol; 2021; 2223():295-335. PubMed ID: 33226602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allergen immunotherapy for allergic asthma: The future seems bright.
    Diamant Z; van Maaren M; Muraro A; Jesenak M; Striz I
    Respir Med; 2023; 210():107125. PubMed ID: 36702170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. House dust mite SCIT reduces asthma risk and significantly improves long-term rhinitis and asthma control-A RWE study.
    Jutel M; Klimek L; Richter H; Brüggenjürgen B; Vogelberg C
    Allergy; 2024 Apr; 79(4):1042-1051. PubMed ID: 38429981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asthma, Airway Symptoms and Rhinitis in Office Workers in Malaysia: Associations with House Dust Mite (HDM) Allergy, Cat Allergy and Levels of House Dust Mite Allergens in Office Dust.
    Lim FL; Hashim Z; Than LT; Md Said S; Hisham Hashim J; Norbäck D
    PLoS One; 2015; 10(4):e0124905. PubMed ID: 25923543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy.
    Baron-Bodo V; Batard T; Nguyen H; Fréreux M; Horiot S; Harwanegg C; Bergmann KC; de Beaumont O; Moingeon P
    Clin Exp Allergy; 2012 Oct; 42(10):1510-8. PubMed ID: 22994348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The impact of subcutaneous immunotherapy with Dermatophagoides farinae and Dermatophagoides pteronyssinus on the quality of life of patients with allergic rhinitis and asthma].
    Yepes-Núñez JJ; Gómez C; Espinoza Y; Cardona R
    Biomedica; 2014; 34(2):282-90. PubMed ID: 24967933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens.
    Potapova E; Bordas-Le Floch V; Schlederer T; Vrtala S; Huang HJ; Canonica GW; Valenta R; Matricardi PM; Mascarell L
    Allergy; 2022 Oct; 77(10):3084-3095. PubMed ID: 35474582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and safety of sublingual immunotherapy with house dust mite extract in poly allergen sensitized children with allergic rhinitis].
    Zhou L; Wang J; Chen Y; Luo R; Tao J; Nie M; Liu B; Li Y
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Oct; 26(20):913-6. PubMed ID: 23272490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel routes for allergen immunotherapy: safety, efficacy and mode of action.
    Moingeon P; Mascarell L
    Immunotherapy; 2012 Feb; 4(2):201-12. PubMed ID: 22339462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma.
    Hesse L; Nawijn MC
    Methods Mol Biol; 2017; 1559():137-168. PubMed ID: 28063043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.